Third Rock Ventures Iv, L.p. - Net Worth and Insider Trading

Third Rock Ventures Iv, L.p. Net Worth

The estimated net worth of Third Rock Ventures Iv, L.p. is at least $94 Million dollars as of 2024-11-05. Third Rock Ventures Iv, L.p. is the 10% Owner of Tango Therapeutics Inc and owns about 16,859,075 shares of Tango Therapeutics Inc (TNGX) stock worth over $84 Million. Third Rock Ventures Iv, L.p. is the 10% Owner of Fulcrum Therapeutics Inc and owns about 2,343,154 shares of Fulcrum Therapeutics Inc (FULC) stock worth over $8 Million. Third Rock Ventures Iv, L.p. is also the 10% Owner of Magenta Therapeutics Inc and owns about 3,058,204 shares of Magenta Therapeutics Inc (MGTA) stock worth over $2 Million. Details can be seen in Third Rock Ventures Iv, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Third Rock Ventures Iv, L.p. has not made any transactions after 2024-09-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Third Rock Ventures Iv, L.p.

To

Third Rock Ventures Iv, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Third Rock Ventures Iv, L.p. owns 6 companies in total, including Relay Therapeutics Inc (RLAY) , Pliant Therapeutics Inc (PLRX) , and Revolution Medicines Inc (RVMD) among others .

Click here to see the complete history of Third Rock Ventures Iv, L.p.’s form 4 insider trades.

Insider Ownership Summary of Third Rock Ventures Iv, L.p.

Ticker Comapny Transaction Date Type of Owner
RLAY Relay Therapeutics Inc 2020-07-15 10 percent owner
PLRX Pliant Therapeutics Inc 2020-06-02 10 percent owner
RVMD Revolution Medicines Inc 2020-02-12 10 percent owner
LIMIT LIMIT 2019-07-22 10 percent owner
LIMIT LIMIT 2023-02-08 10 percent owner
LIMIT LIMIT 2024-09-13 10 percent owner

Third Rock Ventures Iv, L.p. Latest Holdings Summary

Third Rock Ventures Iv, L.p. currently owns a total of 3 stocks. Among these stocks, Third Rock Ventures Iv, L.p. owns 16,859,075 shares of Tango Therapeutics Inc (TNGX) as of September 13, 2024, with a value of $84 Million and a weighting of 89.64%. Third Rock Ventures Iv, L.p. owns 2,343,154 shares of Fulcrum Therapeutics Inc (FULC) as of July 22, 2019, with a value of $8 Million and a weighting of 8.09%. Third Rock Ventures Iv, L.p. also owns 3,058,204 shares of Magenta Therapeutics Inc (MGTA) as of February 8, 2023, with a value of $2 Million and a weighting of 2.28%.

Latest Holdings of Third Rock Ventures Iv, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TNGX Tango Therapeutics Inc 2024-09-13 16,859,075 5.00 84,295,375
FULC Fulcrum Therapeutics Inc 2019-07-22 2,343,154 3.25 7,603,535
MGTA Magenta Therapeutics Inc 2023-02-08 3,058,204 0.70 2,139,520

Holding Weightings of Third Rock Ventures Iv, L.p.


Third Rock Ventures Iv, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Third Rock Ventures Iv, L.p. has made a total of 12 transactions in Tango Therapeutics Inc (TNGX) over the past 5 years, including 0 buys and 12 sells. The most-recent trade in Tango Therapeutics Inc is the sale of 67,400 shares on September 13, 2024, which brought Third Rock Ventures Iv, L.p. around $709,722.

According to the SEC Form 4 filings, Third Rock Ventures Iv, L.p. has made a total of 0 transactions in Fulcrum Therapeutics Inc (FULC) over the past 5 years. The most-recent trade in Fulcrum Therapeutics Inc is the acquisition of 81,250 shares on July 22, 2019, which cost Third Rock Ventures Iv, L.p. around $1 Million.

According to the SEC Form 4 filings, Third Rock Ventures Iv, L.p. has made a total of 1 transactions in Magenta Therapeutics Inc (MGTA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Magenta Therapeutics Inc is the sale of 3,700,000 shares on February 8, 2023, which brought Third Rock Ventures Iv, L.p. around $3 Million.

Insider Trading History of Third Rock Ventures Iv, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Third Rock Ventures Iv, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Third Rock Ventures Iv, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Third Rock Ventures Iv, L.p. is -59.61%. GuruFocus also compares Third Rock Ventures Iv, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Third Rock Ventures Iv, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Third Rock Ventures Iv, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Third Rock Ventures Iv, L.p.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -9.3 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -7.22 LIMIT LIMIT LIMIT LIMIT LIMIT

Third Rock Ventures Iv, L.p. Ownership Network

Ownership Network List of Third Rock Ventures Iv, L.p.

No Data

Ownership Network Relation of Third Rock Ventures Iv, L.p.

Insider Network Chart

Third Rock Ventures Iv, L.p. Owned Company Details

What does Relay Therapeutics Inc do?

Who are the key executives at Relay Therapeutics Inc?

Third Rock Ventures Iv, L.p. is the 10 percent owner of Relay Therapeutics Inc. Other key executives at Relay Therapeutics Inc include Vice President & Finance Thomas Catinazzo , See remarks Peter Rahmer , and See Remarks Donald A Bergstrom .

Relay Therapeutics Inc (RLAY) Insider Trades Summary

Over the past 18 months, Third Rock Ventures Iv, L.p. made no insider transaction in Relay Therapeutics Inc (RLAY). Other recent insider transactions involving Relay Therapeutics Inc (RLAY) include a net sale of 132,111 shares made by Peter Rahmer , a net sale of 44,032 shares made by Thomas Catinazzo , and a net sale of 18,539 shares made by Donald A Bergstrom .

In summary, during the past 3 months, insiders sold 22,688 shares of Relay Therapeutics Inc (RLAY) in total and bought 0 shares, with a net sale of 22,688 shares. During the past 18 months, 291,361 shares of Relay Therapeutics Inc (RLAY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 291,361 shares.

Relay Therapeutics Inc (RLAY)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Relay Therapeutics Inc Insider Transactions

No Available Data

Third Rock Ventures Iv, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Third Rock Ventures Iv, L.p.. You might contact Third Rock Ventures Iv, L.p. via mailing address: 29 Newbury Street, 3rd Floor, Boston Ma 02116.